Literature DB >> 10794486

Urinary pharmacokinetics of the glucuronide and sulfate conjugates of genistein and daidzein.

S R Shelnutt1, C O Cimino, P A Wiggins, T M Badger.   

Abstract

Consumption of soybean-rich diets is thought to provide significant health benefits such as prevention of cancer, primarily because of the high contents of factors such as the isoflavones genistein and daidzein. Isoflavones circulate and are excreted into the urine mainly as glucuronide and sulfate conjugates. This study was conducted to determine the urinary pharmacokinetics of sulfate and glucuronide conjugates of genistein and daidzein. Twelve volunteers consumed a soy beverage providing 1 and 0.6 mg/kg body weight of genistein and daidzein equivalents, respectively. Urine was collected at various times during the 48 h after soy consumption and was digested with either glucuronidase or sulfatase, and the liberated aglycones were extracted and analyzed by liquid chromatography-mass spectrometry. Urinary isoflavone sulfate levels were determined by two methods: (a) assessment of aglycone after sulfatase hydrolysis (measured); or (b) calculated by subtracting the aglycone + glucuronide levels from the total urinary isoflavone levels. The apparent terminal half-life for daidzein sulfate (3.9+/-0.5 h) that was determined from sulfatase-treated urine was 32% shorter (P < or = 0.02) than that of the calculated daidzein sulfate (5.7+/-0.08 h). A similar trend was obtained for genistein sulfate (4.5+/-0.7 versus 6.8+/-0.1 h). The apparent terminal half-lives for genistein and daidzein glucuronides were 6.0+/-0.4 and 3.8+/-0.4 h, respectively. These data suggest that the measured urinary isoflavone sulfate values provide a better understanding of the pharmacokinetics than the calculated values. Additional studies are needed to determine whether the apparent terminal half-lives can be attributed to elimination or absorption processes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10794486

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  14 in total

Review 1.  Equol: history, chemistry, and formation.

Authors:  Kenneth D R Setchell; Carlo Clerici
Journal:  J Nutr       Date:  2010-06-02       Impact factor: 4.798

2.  Soy isoflavone phase II metabolism differs between rodents and humans: implications for the effect on breast cancer risk.

Authors:  Kenneth D R Setchell; Nadine M Brown; Xueheng Zhao; Stephanie L Lindley; James E Heubi; Eileen C King; Mark J Messina
Journal:  Am J Clin Nutr       Date:  2011-09-28       Impact factor: 7.045

3.  Breast cancer resistance protein (ABCG2) determines distribution of genistein phase II metabolites: reevaluation of the roles of ABCG2 in the disposition of genistein.

Authors:  Zhen Yang; Wei Zhu; Song Gao; Taijun Yin; Wen Jiang; Ming Hu
Journal:  Drug Metab Dispos       Date:  2012-06-26       Impact factor: 3.922

4.  Measurement of bisphenol A, bisphenol A ß-D-glucuronide, genistein, and genistein 4'-ß-D-glucuronide via SPE and HPLC-MS/MS.

Authors:  Janis L Coughlin; Bozena Winnik; Brian Buckley
Journal:  Anal Bioanal Chem       Date:  2011-06-13       Impact factor: 4.142

5.  Enhanced intestinal absorption of daidzein by borneol/menthol eutectic mixture and microemulsion.

Authors:  Qi Shen; Xi Li; Wenji Li; Xinyi Zhao
Journal:  AAPS PharmSciTech       Date:  2011-08-13       Impact factor: 3.246

Review 6.  Equol: pharmacokinetics and biological actions.

Authors:  Kenneth D R Setchell; Carlo Clerici
Journal:  J Nutr       Date:  2010-06-02       Impact factor: 4.798

7.  Selected physiologic variables are weakly to moderately associated with 29 biomarkers of diet and nutrition, NHANES 2003-2006.

Authors:  Bridgette M H Haynes; Christine M Pfeiffer; Maya R Sternberg; Rosemary L Schleicher
Journal:  J Nutr       Date:  2013-04-17       Impact factor: 4.798

Review 8.  Bioavailability and pharmacokinetics of genistein: mechanistic studies on its ADME.

Authors:  Zhen Yang; Kaustubh Kulkarni; Wei Zhu; Ming Hu
Journal:  Anticancer Agents Med Chem       Date:  2012-12       Impact factor: 2.505

9.  Evaluation of CYP450 inhibitory effects and steady-state pharmacokinetics of genistein in combination with cholecalciferol and citrated zinc bisglycinate in postmenopausal women.

Authors:  Bruce P Burnett; Lakshmi Pillai; Alessandra Bitto; Francesco Squadrito; Robert M Levy
Journal:  Int J Womens Health       Date:  2011-05-09

10.  Effect of sulphation on the oestrogen agonist activity of the phytoestrogens genistein and daidzein in MCF-7 human breast cancer cells.

Authors:  D Pugazhendhi; K A Watson; S Mills; N Botting; G S Pope; P D Darbre
Journal:  J Endocrinol       Date:  2008-06       Impact factor: 4.286

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.